Reference is made to the stock exchange notice of 26 November 2009 regarding a private placement and subsequent offering.

 

The final number of subscription rights to be issued to eligible shareholders in the proposed subsequent offering will be 2.38323 subscription rights per share held on 25 November 2009. Shareholders that were invited to participate in the private placement are not eligible and will not receive subscription rights. The subscription rights are tradable and will be listed on Oslo Stock Exchange. The subscription period is expected to start on 22 December 2009 and to end at 17:30 (CET) on 12 January 2010.

 

Both the private placement and the subsequent offering are subject to approval by the extraordinary general meeting, to be held on 18 December 2009, see stock exchange notice of 27 November 2009. The shareholders that participated in the private placement have undertaken to vote in favour of the proposed transaction. They represent 58.9 per cent of the total number of shares in NorDiag ASA.

 

The above issuance of subscription rights will be reflected in the proposed resolutions to the extraordinary general meeting regarding the subsequent offering. In line with the notice of the extraordinary general meeting, the resolution regarding amendment of the exercise terms for Class B Warrants and Class C Warrants (item 5.III) is updated as follows:

 

"The Board proposes that the General Meeting resolves the following:

 

a) Provided that the private placement and the repair issue is completed, each Class B Warrant shall give the right to require issued 3.38323 new shares in the Company, each with a nominal value of NOK 1, at a subscription price of NOK 2.18 per share, provided that fractional shares will not be issued. The first exercise period with amended terms is 15-31 March 2010.

 

b) Provided that the private placement and the repair issue is completed, each Class C Warrant gives the right to require issued 3.38323 new shares in the Company, each with a nominal value of NOK 1, at a subscription price of NOK 2.18 per share, provided that fractional shares will not be issued. The first exercise period with amended terms is 15-30 June 2010.

 

c) In other respects, the terms of Class B Warrants and Class C Warrants are unaltered."

 

 

Contact:      CEO Mårten Wigstøl            Phone: +47 911 65775

                   CFO Tone Kvåle                 Phone: +47 915 19576

 

 

 

 

 

NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and tests) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and it is the fastest growing field within diagnostics. The company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information - www.nordiag.com.